Results 11 to 20 of about 22,949 (256)

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24‐month interim analysis of a long‐term post‐marketing study (J‐STEP/LT)

Journal of Diabetes Investigation, 2020
Aims/Introduction Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor, and is currently used to treat patients with type 2 diabetes mellitus. We designed a 3‐year study of tofogliflozin in patients with type 2 diabetes
Kazunori Utsunomiya, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Ryusuke Koshida, Hiroyuki Kameda, Masahiro Tamura, Kohei Kaku   +9 more
doaj   +1 more source

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world practice: Results of 12‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT)

Journal of Diabetes Investigation, 2020
Aims/Introduction Due to the paucity of tofogliflozin data, we assessed the safety and effectiveness of tofogliflozin among Japanese patients with type 2 diabetes mellitus in the clinical setting, stratifying the patients by age, sex, estimated ...
Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi, Hiroyuki Kameda, Masahiro Tamura, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Kohei Kaku   +8 more
doaj   +1 more source

Repeat confirmatory testing for persons with discordant whole blood and oral fluid rapid HIV test results: findings from post marketing surveillance. [PDF]

PLoS ONE, 2008
BACKGROUND: Reactive oral fluid and whole blood rapid HIV tests must be followed with a confirmatory test (Western blot (WB), immunofluorescent assay (IFA) or approved nucleic acid amplification test (NAAT)).
Laura G Wesolowski, Duncan A Mackellar, Steven F Ethridge, Julia H Zhu, S Michele Owen, Patrick S Sullivan, Post Marketing Surveillance Team   +6 more
doaj   +1 more source

Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post‐marketing study (J‐STEP/EL Study)

Journal of Diabetes Investigation, 2020
Aims/Introduction This subanalysis aimed to assess the safety and effectiveness of tofogliflozin by using data from the Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients in an Observational Study of the Elderly to categorize elderly ...
Kohei Kaku, Yusuke Naito, Masayuki Senda, Yuji Kurihara, Ryoji Gunji, Seigo Kakiuchi, Kazunori Utsunomiya   +6 more
doaj   +1 more source

Post marketing surveillance of selected veterinary medicines in Tanzania mainland

BMC Veterinary Research, 2022
Background Veterinary medicines have been widely used for the prevention and treatment of animal diseases. Globally, the veterinary medicine industry is growing.
Adam M. Fimbo, Betty A. Maganda, Kissa W. Mwamwitwa, Itikija E. Mwanga, Engelbert B. Mbekenga, Seth Kisenge, Sophia A. Mziray, Gerald S. Kulwa, Yonah H. Mwalwisi, Danstan H. Shewiyo   +9 more
doaj   +1 more source

Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice: Results of 3‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT)

Journal of Diabetes Investigation, 2019
Aims/Introduction The present study analysis was carried out to evaluate the safety and efficacy of tofogliflozin, a sodium–glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice.
Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi, Hiroyuki Kameda, Masahiro Tamura, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Hisataka Fujiwara, Kohei Kaku   +9 more
doaj   +1 more source

Post-marketing safety surveillance of the rotavirus vaccine in India

Vaccine: X, 2023
Background: ROTASIIL, an oral live attenuated bovine-human reassortant pentavalent rotavirus vaccine, was approved in 2017. This post-marketing surveillance (PMS) was conducted to collect real-world data on the safety of ROTASIIL in India.
Gagandeep Kang, Anand Lakhkar, Chetanraj Bhamare, Abhijeet Dharmadhikari, Jyoti Narwadkar, Arti Kanujia, Sajjad Desai, Bhagwat Gunale, Cyrus S. Poonawalla, Prasad S. Kulkarni   +9 more
doaj   +1 more source

Long-term post-marketing surveillance of mizoribine for the treatment of lupus nephritis: Safety and efficacy during a 3-year follow-up

SAGE Open Medicine, 2014
Objective: To determine the safety and efficacy of long-term use of mizoribine by undertaking a 3-year post-marketing surveillance study. Methods: Subjects were all lupus nephritis patients newly treated with mizoribine between 1 October 2003 and 30 ...
Nobuyuki Yagi, Kenya Okada, Yohei Sudo, Hiromichi Itoh, Hisao Yoshida, Tatsuhiko Kuroda   +5 more
doaj   +1 more source

Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk

Osteoporosis and Sarcopenia, 2019
Objectives: To reassess the safety and efficacy of once-weekly teriparatide 56.5 μg in osteoporosis patients with a high fracture risk. Methods: This postmarketing observational study was conducted at 72 weeks according to the package insert. Of the 3573
Emiko Ifuku, Takeshi Yoshimura, Toyonobu Uzawa, Tadami Hokonohara   +3 more
doaj   +1 more source

A multi-centre, post-marketing surveillance study of Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar TCV®) in India

Human Vaccines & Immunotherapeutics, 2022
A typhoid Vi capsular-polysaccharide tetanus toxoid conjugate vaccine (Typbar-TCV®) was recommended by the World Health Organization for use in children >6 months of age.
Raghu Reddy, Bhargav Reddy, Vamshi Sarangi, Siddharth Reddy, Raches Ella, Krishna Mohan Vadrevu   +5 more
doaj   +1 more source